Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of CinRx Pharma.

    Client Virtual Booth

    CINRX PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    CinRx Pharma
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5375 Medpace Way Cincinnati, OH 45227
    Telephone
    Telephone
    844-531-1834
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.cinrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cinrx-pharma/
    Twitter
    Twitter
    https://twitter.com/CinRx_Pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatmen...

    Details:

    CIN-110 is a potent and highly selective large molecule peptide and a PYY3-36 analog, which is currently under development for the treatment of Obesity.


    Lead Product(s): CIN-110

    Therapeutic Area: Nutrition and Weight Loss Product Name: CIN-110

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 26, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

    Details:

    The net proceeds will be used to develop CinDome Pharma’s Phase 2 envision3D study of CIN-102 (deudomperidone), a new chemical entity based upon deuteration and novel formulation of domperidone in patients with diabetic gastroparesis.


    Lead Product(s): Deudomperidone

    Therapeutic Area: Gastroenterology Product Name: CIN-102

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: CinRx Pharma & Perceptive Advisors

    Deal Size: $19.0 million Upfront Cash: Undisclosed

    Deal Type: Private Placement April 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

    Details:

    CIN-102 (deudomperidone) is a new chemical entity based upon deuteration and novel formulation of domperidone (DA2-receptor antagonist), a frequently prescribed first line therapy for nausea, vomiting, and gastroparesis outside of the United States.


    Lead Product(s): Deudomperidone

    Therapeutic Area: Gastroenterology Product Name: CIN-102

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CinFina Pharma In-Licenses Obesity Portfolio

    Details:

    Under the agreement CinFina will be responsible for development, manufacturing and commercialization of CIN-109, with a multiple ascending dose Phase 1 clinical study, and following dose selection, will commence a Phase 2 study in overweight and obese adults in the US.


    Lead Product(s): CIN-109

    Therapeutic Area: Nutrition and Weight Loss Product Name: CIN-109

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Janssen Sciences Ireland Unlimited

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement September 22, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search